Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
Last Updated on: 24 November, 2024
Author: Getaka|Social: Getaka Financial Services X (Earlier Twitter) Profile Getaka Financial Services LinkedIn Logo
Stock Ticker - BSE: 543332 | NSE: EPIGRAL

Epigral Ltd: Intrinsic Value and Fundamental Analysis

Share Price and Basic Stock Data

Last Updated: November 22, 2024, 8:39 pm

Market Cap 8,360 Cr.
Current Price 1,947
High / Low2,408/886
Stock P/E28.6
Book Value 337
Dividend Yield0.26 %
ROCE17.5 %
ROE16.9 %
Face Value 10.0
PEG Ratio1.45

Stock P/E, Current Price, and Intrinsic Value Over Time

View Share Price Target for Epigral Ltd

Competitors of Epigral Ltd

Stock NameMarket CapCurrent PriceHigh / LowStock P/EBook ValueDividend YieldROCEROEFace Value
Epigral Ltd 8,360 Cr. 1,9472,408/88628.6 3370.26 %17.5 %16.9 % 10.0
Dharmaj Crop Guard Ltd 970 Cr. 287390/19724.0 1170.00 %14.5 %13.2 % 10.0
Bhaskar Agrochemicals Ltd 36.6 Cr. 70.3122/46.118.6 29.20.00 %14.7 %13.4 % 10.0
Bhagiradha Chemicals & Industries Ltd 4,065 Cr. 328448/117151 51.00.03 %9.69 %6.27 % 1.00
Best Agrolife Ltd 1,410 Cr. 595918/45438.3 3200.50 %16.5 %18.1 % 10.0
Industry Average11,996.74 Cr1,761.7442.05387.580.31%13.80%15.51%7.35

All Competitor Stocks of Epigral Ltd

Quarterly Result

MonthJun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024
Sales290340422499533556538562455478472525651
Expenses198239281324345375371407360370349369475
Operating Profit9210114117518718016715595108123155176
OPM %32%30%33%35%35%32%31%28%21%23%26%30%27%
Other Income02-0222-0521222
Interest12101012111421191821201414
Depreciation21222221222631303132313033
Profit before tax5971109144156142114110485674113131
Tax %37%34%36%31%31%35%33%30%33%32%34%32%34%
Net Profit374770991089277773238497786
EPS in Rs8.9011.3116.7823.8525.9422.0418.5818.487.629.1811.8718.4520.70

Last Updated: Unknown

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: Unknown

MonthMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024TTM
Sales3943925987106118291,5512,1881,9292,126
Expenses2452483464054165671,0411,4991,4481,563
Operating Profit149144252306194261510689481562
OPM %38%37%42%43%32%32%33%31%25%26%
Other Income21816224867
Interest1914925112944667369
Depreciation44555554447486109124126
Profit before tax8875195242141161383523291374
Tax %23%11%20%25%21%37%34%32%33%
Net Profit6767155183112101253353196250
EPS in Rs9.499.4021.9744.3827.1924.4860.8485.0447.1260.20
Dividend Payout %0%0%0%0%0%0%0%6%11%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year2016-20172017-20182018-20192019-20202020-20212021-20222022-20232023-2024
YoY Net Profit Growth (%)0.00%131.34%18.06%-38.80%-9.82%150.50%39.53%-44.48%
Change in YoY Net Profit Growth (%)0.00%131.34%-113.28%-56.86%28.98%160.32%-110.97%-84.00%

Epigral Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 8 years from 2016-2017 to 2023-2024.

Growth

Compounded Sales Growth
10 Years:%
5 Years:22%
3 Years:33%
TTM:12%
Compounded Profit Growth
10 Years:%
5 Years:2%
3 Years:25%
TTM:31%
Stock Price CAGR
10 Years:%
5 Years:%
3 Years:41%
1 Year:112%
Return on Equity
10 Years:%
5 Years:30%
3 Years:30%
Last Year:17%

Last Updated: Unknown

Balance Sheet

Last Updated: November 14, 2024, 4:32 pm

MonthMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Sep 2024
Equity Capital71717141424242424242
Reserves2242914472413314326841,0281,2131,358
Borrowings19012374601737753993879964904
Other Liabilities554279162164223405484576676
Total Liabilities5405276711,0441,2731,4492,1242,4322,7942,979
Fixed Assets3643983472954401,1021,0681,8041,7671,912
CWIP69379468691126589158483350
Investments029710000212121
Other Assets10698173281142221467449524696
Total Assets5405276711,0441,2731,4492,1242,4322,7942,979

Reserves and Borrowings Chart

Cash Flow

MonthMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024
Cash from Operating Activity +165229284626398
Cash from Investing Activity +-363-197-455-437-401
Cash from Financing Activity +69-32195-200-8
Net Cash Flow-129124-11-11

Free Cash Flow

MonthMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024
Free Cash Flow-41.0021.00178.00-295.00-543.00-492.00-483.00-190.00-483.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

MonthMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024
Debtor Days434147404652602834
Inventory Days755945586451746990
Days Payable313751526269423657
Cash Conversion Cycle866342464834926167
Working Capital Days434019-26-65-59261525
ROCE %18%37%36%15%16%29%32%17%

Financial Efficiency Indicators Chart

Share Holding Pattern

MonthSep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024
Promoters72.62%71.19%71.18%71.11%71.12%71.21%71.34%71.37%71.38%71.38%71.49%71.58%
FIIs0.78%1.16%1.02%1.38%1.40%1.15%1.20%1.16%1.14%1.17%1.36%1.46%
DIIs0.00%0.00%0.47%0.22%0.19%0.17%0.03%0.04%0.04%0.05%0.02%0.18%
Government0.00%0.00%0.02%0.02%0.02%0.02%0.02%0.02%0.02%0.02%0.02%0.02%
Public26.59%27.66%27.31%27.27%27.26%27.44%27.39%27.39%27.40%27.37%27.10%26.75%
No. of Shareholders1,00,42198,57892,18593,14797,39697,01694,77895,83395,74292,95988,87085,761

Shareholding Pattern Chart

No. of Shareholders

This stock is not held by any mutual fund

ROCE Trend

EPS Trend

Key Financial Ratios

MonthMar 24Mar 23Mar 22Mar 21
FaceValue10.0010.0010.0010.00
Basic EPS (Rs.)47.1485.0360.8424.27
Diluted EPS (Rs.)47.1485.0360.8424.27
Cash EPS (Rs.)76.87111.2581.5141.97
Book Value[Excl.RevalReserv]/Share (Rs.)301.83257.30174.72113.88
Book Value[Incl.RevalReserv]/Share (Rs.)301.83257.30174.72113.88
Revenue From Operations / Share (Rs.)464.30526.69373.27199.41
PBDIT / Share (Rs.)117.39167.73123.6163.42
PBIT / Share (Rs.)87.66141.51102.9345.72
PBT / Share (Rs.)69.97125.7592.2838.71
Net Profit / Share (Rs.)47.1385.0360.8424.27
NP After MI And SOA / Share (Rs.)47.1485.0360.8424.27
PBDIT Margin (%)25.2831.8433.1131.80
PBIT Margin (%)18.8726.8627.5722.92
PBT Margin (%)15.0623.8724.7219.41
Net Profit Margin (%)10.1516.1416.2912.16
NP After MI And SOA Margin (%)10.1516.1416.2912.16
Return on Networth / Equity (%)15.6133.0434.8221.30
Return on Capital Employeed (%)18.0732.9426.8717.92
Return On Assets (%)7.0014.5211.906.96
Long Term Debt / Equity (X)0.390.401.060.71
Total Debt / Equity (X)0.720.711.360.87
Asset Turnover Ratio (%)0.730.960.860.00
Current Ratio (X)0.640.640.830.46
Quick Ratio (X)0.300.320.550.32
Inventory Turnover Ratio (X)4.516.627.300.00
Dividend Payout Ratio (NP) (%)5.302.940.000.00
Dividend Payout Ratio (CP) (%)3.252.240.000.00
Earning Retention Ratio (%)94.7097.060.000.00
Cash Earning Retention Ratio (%)96.7597.760.000.00
Interest Coverage Ratio (X)6.6410.6411.609.05
Interest Coverage Ratio (Post Tax) (X)3.666.396.714.46
Enterprise Value (Cr.)5509.594780.475010.230.00
EV / Net Operating Revenue (X)2.862.183.230.00
EV / EBITDA (X)11.306.869.760.00
MarketCap / Net Operating Revenue (X)2.361.792.610.00
Retention Ratios (%)94.6997.050.000.00
Price / BV (X)3.633.675.570.00
Price / Net Operating Revenue (X)2.361.792.610.00
EarningsYield0.040.090.060.00

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

Fair Value

Fair Value of Epigral Ltd as of November 24, 2024 is: 1,633.09

Calculation basis:

  • Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.

As of November 24, 2024, Epigral Ltd is Overvalued by 16.12% compared to the current share price 1,947.00

Intrinsic Value of Epigral Ltd as of November 24, 2024 is: 1,955.09

Calculation basis:

  • Intrinsic value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
  • EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.

This formula allows us to gauge the intrinsic value of the stock by analyzing its fundamental indicators along with EPS growth.

As of November 24, 2024, Epigral Ltd is Undervalued by 0.42% compared to the current share price 1,947.00

Last 5 Year EPS CAGR: 19.72%

*Investments are subject to market risks

Strength and Weakness

StrengthWeakness
  1. The stock has a high average ROCE of 22.22%, which is a positive sign.
  2. The stock has a low average Working Capital Days of 2.00, which is a positive sign.
  3. The company has higher reserves (624.90 cr) compared to borrowings (621.80 cr), indicating strong financial stability.
  4. The company has shown consistent growth in sales (354.00 cr) and profit (247.30 cr) over the years.
  1. The stock has a high average Cash Conversion Cycle of 59.89, which may not be favorable.

Stock Analysis

  • Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Epigral Ltd:
    1. Net Profit Margin: 10.15%
      • Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
    2. ROCE: 18.07% (Industry Average ROCE: 13.8%)
      • ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
    3. ROE%: 15.61% (Industry Average ROE: 15.51%)
      • ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
    4. Interest Coverage Ratio (Post Tax): 3.66
      • Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
    5. Quick Ratio: 0.3
      • Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
    6. Stock P/E: 28.6 (Industry average Stock P/E: 42.05)
      • Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
    7. Total Debt / Equity: 0.72
      • Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
    The current analysis is available for review. It's important to conduct thorough research and consider consulting with financial professionals before making any investment decisions.
    Stock Rating:

About the Company - Qualitative Analysis

Meghmani Finechem Ltd. is a Public Limited Listed company incorporated on 11/09/2007 and has its registered office in the State of Gujarat, India. Company’s Corporate Identification Number(CIN) is L24100GJ2007PLC051717 and registration number is 051717. Currently Company is involved in the business activities of Manufacture of organic and inorganic chemical compounds. Company’s Total Operating Revenue is Rs. 1550.94 Cr. and Equity Capital is Rs. 41.55 Cr. for the Year ended 31/03/2022.
INDUSTRYADDRESSCONTACT
Agro Chemicals/Pesticides�Epigral Tower�, Behind Safal Profitaire, Ahmedabad Gujarat 380015helpdesk@epigral.com
http://www.epigral.com
Management
NamePosition Held
Mr. Maulik Jayantibhai PatelChairman & Managing Director
Mr. Kaushal Ashish SoparkarExecutive Director
Mr. Ankit Natwarlal PatelNon Exe.Non Ind.Director
Mr. Karana Rameshbhai PatelNon Exe.Non Ind.Director
Mr. Darshan Anandbhai PatelNon Exe.Non Ind.Director
Mr. Manubhai PatelIndependent Director
Mr. Sanjay AsherIndependent Director
Mr. Kanubhai Shakarabhai PatelIndependent Director
Mr. Raju SwamyIndependent Director
Ms. Nirali ParikhIndependent Director

FAQ

What is the latest intrinsic value of Epigral Ltd?

The latest intrinsic value of Epigral Ltd as on 24 November 2024 is ₹1633.09, which is 16.12% lower than the current market price of ₹1,947.00.

What is the Market Cap of Epigral Ltd?

The Market Cap of Epigral Ltd is 8,360 Cr..

What is the current Stock Price of Epigral Ltd as on 24 November 2024?

The current stock price of Epigral Ltd as on 24 November 2024 is 1,947.

What is the High / Low of Epigral Ltd stocks in FY 2024?

In FY 2024, the High / Low of Epigral Ltd stocks is 2,408/886.

What is the Stock P/E of Epigral Ltd?

The Stock P/E of Epigral Ltd is 28.6.

What is the Book Value of Epigral Ltd?

The Book Value of Epigral Ltd is 337.

What is the Dividend Yield of Epigral Ltd?

The Dividend Yield of Epigral Ltd is 0.26 %.

What is the ROCE of Epigral Ltd?

The ROCE of Epigral Ltd is 17.5 %.

What is the ROE of Epigral Ltd?

The ROE of Epigral Ltd is 16.9 %.

What is the Face Value of Epigral Ltd?

The Face Value of Epigral Ltd is 10.0.

About the Author

Author Avatar
Getaka

Getaka, CFA, a financial analyst with 15 years of experience in the industry. Getaka holds an MBA degree and the Chartered Financial Analyst designation, demonstrating his profound understanding of financial analysis and investment management. Throughout his career, he has conducted numerous financial analyses and due diligence processes for companies in the industry, and has a strong track record of identifying key trends and opportunities. He leverages his expertise to deliver a thorough financial analysis of a company, encompassing its financial performance, key ratios, future prospects, and risks. Getaka is committed to providing accurate, reliable, and trustworthy information to help readers make informed decisions about their finances and investments.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Epigral Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE